Opus Genetics

This past weekend, Opus was proud to participate in the Foundation Fighting Blindness Investing in Cures Summit—an inspiring and impactful gathering of?inherited #retinal disease (#IRD) specialists, biotech leaders, patients, families and advocates, all united by a shared mission to accelerate progress toward restoring and preserving #vision. Thank you to the Foundation for convening these important conversations. We’re honored to be part of this dedicated community working to translate?scientific possibility into meaningful outcomes for patients. ??: Opus Chief Scientific and Development Officer Ash Jayagopal, Ph.D., presenting at Investing in Cures

Opus today announced the pricing of an underwritten public offering with gross proceeds of $20 million and concurrent private placement with gross proceeds of $1.5 million, with up to $21.4 million in additional proceeds upon exercise of warrants. Read the press release: https://lnkd.in/ePyDNb2W

Opus today announced the pricing of an underwritten public offering with gross proceeds of $20 million and concurrent private placement with gross proceeds of $1.5 million, with up to $21.4 million in additional proceeds upon exercise of warrants. Read the press release: https://lnkd.in/ePyDNb2W

???Watch the seventh in a?series?of highlights from Opus’ recent Key Opinion Leader event around advancing #genetherapies for inherited retinal diseases (#IRD). In this video, Tomas Aleman, MD,?discusses current safety data seen in the ongoing first-in-human, open-label, Phase 1/2 trial of OPGx-LCA5, as well as industry-wide safety trends observed across the development of ophthalmic gene therapies. Watch it here ?? https://lnkd.in/e6dy2UcT Interested in the full conversation? Watch the replay here??? https://lnkd.in/eh_jEqdY

?? Watch the sixth in a?series?of highlights from Opus’ recent Key Opinion Leader event around advancing #genetherapies for inherited retinal diseases (#IRD). ? In this video, Tomas Aleman, MD and Christine Kay, MD,?discuss gene therapy treatments for IRDs and the potential for them to become the standard of care for this patient population.?Gene therapy for IRDs is advancing rapidly as they continue to demonstrate clinical promise, with the strong safety profile of retinal delivery supported by FDA approvals and promising Phase 1/2?trials. As the field progresses toward broader adoption, continued success lies in remaining adaptable, recognizing the unique needs of each patient and evolving approaches accordingly. Watch it here??? https://lnkd.in/e3mTKD4c Interested in the full conversation? Watch the replay here??? https://lnkd.in/eh_jEqdY

?? We're pleased to announce that three abstracts on our investigational gene therapy candidates have been accepted for presentation at the?Association for Research in Vision and Ophthalmology (ARVO) 2025 Meeting, to take place May 4-8, 2025. The abstracts feature 12-month data from the first three adult patients in our ongoing Phase 1/2 trial of OPGx-LCA5, as well as pre-clinical results on OPGx-MERTK and OPGx-RDH12. Read more here ?? https://lnkd.in/efc7Zwqd #ARVO2025 #LCA5 #genetherapy

???Rare Disease Day recognizes the?300 million people worldwide affected by rare diseases—including those living with?inherited retinal diseases (IRDs). At Opus, we are dedicated to?developing life-changing #genetherapies?for rare IRDs, including #LCA5 and #BEST1, to preserve and restore sight for patients who currently have no approved treatments. This year’s theme,?"More Than You Can Imagine,"?highlights the vast impact of rare diseases and the importance of research, innovation, and advocacy in driving progress.?Together with patients, caregivers, researchers, and advocates, we celebrate our work toward a better future for the rare disease community.??? #RareDiseaseDay #MoreThanYouCanImagine?#RareDiseaseDay2025 #LightUpForRare

Opus today announced progress across our Phentolamine Ophthalmic Solution 0.75% programs:? ???Presbyopia:?enrollment in the?VEGA-3 Phase 3 clinical trial evaluating?Phentolamine Ophthalmic Solution 0.75% for #presbyopia is complete ???Low light conditions: the FDA has granted #FastTrack designation for Phentolamine Ophthalmic Solution 0.75% as treatment of significant chronic night driving impairment in keratorefractive patients with reduced mesopic vision; and completion of enrollment in the LYNX-2 pivotal Phase 3 trial evaluating?Phentolamine Ophthalmic Solution 0.75%?for the treatment of visual loss in low light conditions associated with keratorefractive surgery is anticipated in the first half of 2025 ? Read the press release here??? https://lnkd.in/eHEcR4ps

???Watch the fifth in a?series?of highlights from Opus’ recent Key Opinion Leader event around advancing #genetherapies for inherited retinal diseases (#IRDs). In this video,?Opus Chief Scientific and Development Officer Ash Jayagopal, Ph.D., and Arshad M. Khanani, MD,?MA, FASRS, discuss translating scientific advances into successful clinical development programs, including:? ?? addressing the key challenge -?and opportunity - to successful translation of ocular gene therapies with the development of real-world disease-tailored endpoints ?? the potential of the Multi-Luminance orientation and Mobility Test (MLoMT) to guide?the evaluation of novel gene therapies ?? benefits of using validated delivery mechanisms in ocular gene therapy? ? Watch it here ?? https://lnkd.in/e4yxEPFM Interested in the full conversation? Watch the replay here??? https://lnkd.in/eh_jEqdY

Today we announced exciting updates on our?OPGx-LCA5 clinical program: ?? First patient dosed in the pediatric cohort of the Phase 1/2 trial of OPGx-LCA5; initial data on the cohort anticipated by Q3 2025 ?? New 12-month data on the first three adult OPGx-LCA5 patients to be presented at a major medical conference in Q2 2025 ?? FDA meeting scheduled in March 2025 to discuss Phase 3 trial design and registrational endpoints for OPGx-LCA5 Read the press release here ?? https://lnkd.in/eE9DrCh9